Cost Of Cancer, Diabetes, Blood Pressure Drugs Reduced By Around 25%
Products of major pharmaceuticals firms - including Abbott Healthcare, Cipla, Lupin, Alembic, Alkem Laboratories, Novartis, Biocon, Intas Pharmaceuticals, Hetero Healthcare and erstwhile Ranbaxy (now Sun Pharmaceutical Industries) - will be affected by the new price cap announced by drug price regulator NPPA (National Pharmaceutical Pricing Authority).
The capping of the prices of 56 scheduled formulations of Schedule-I is being carried out under the Drugs (Price Control) Amendment Order, 2016, and retail prices of eight formulations under the Drugs (Prices Control) Order, 2013.
The government fixes the prices of essential drugs based on the simple average of all medicines in a particular therapeutic segment, having sales of more than 1 per cent.
Companies are allowed to hike prices of such drugs by up to 10 per cent in a year.
Set up in 1997, NPPA has been entrusted with the task of fixation/revision of prices of pharmaceutical products, enforcement of provisions of the Drugs (Prices Control) Order and monitoring of prices of controlled and decontrolled drugs.
Comments
Post a Comment